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Optimal anchoring of a foldamer inhibitor of ASF1 
histone chaperone through backbone plasticity
Johanne Mbianda1*†, May Bakail2,3*‡, Christophe André1, Gwenaëlle Moal2,3, Marie E. Perrin2,3, 
Guillaume Pinna2,3, Raphaël Guerois2,3, Francois Becher2, Pierre Legrand4, Seydou Traoré2,3, 
Céline Douat1§, Gilles Guichard1||, Françoise Ochsenbein2,3||
Sequence-specific oligomers with predictable folding patterns, i.e., foldamers, provide new opportunities to 
mimic -helical peptides and design inhibitors of protein-protein interactions. One major hurdle of this strategy 
is to retain the correct orientation of key side chains involved in protein surface recognition. Here, we show that 
the structural plasticity of a foldamer backbone may notably contribute to the required spatial adjustment for 
optimal interaction with the protein surface. By using oligoureas as  helix mimics, we designed a foldamer/peptide 
hybrid inhibitor of histone chaperone ASF1, a key regulator of chromatin dynamics. The crystal structure of its 
complex with ASF1 reveals a notable plasticity of the urea backbone, which adapts to the ASF1 surface to main-
tain the same binding interface. One additional benefit of generating ASF1 ligands with nonpeptide oligourea 
segments is the resistance to proteolysis in human plasma, which was highly improved compared to the cognate 
-helical peptide.
INTRODUCTION
The synthesis of sequence-specific synthetic oligomers that fold into 
well-defined helical structures has opened up enticing opportunities 
for mimicking -helical peptides and addressing some of their lim-
itations in biomedical applications (1–5). The improved resistance 
to proteolysis demonstrated by a number of peptidomimetic fol-
damer backbones including peptoids (6), - and -peptides (7–9), 
-AA-peptides (10), N,N′-linked oligourea foldamers (11), and many 
others (1–4) is a significant advantage that can translate into in-
creased duration of action. Moreover, the use of artificial backbones 
as  helix mimics can lead to ligands with unusual receptor-activation 
profiles (12, 13), inhibitors of protein-protein interactions with in-
creased selectivity (14) and cell permeability (10, 15). However, one 
challenge associated with the use of foldamers for specific recogni-
tion of protein surface is to position the side chains at the surface of 
the foldamer with the correct spacing and orientation to maintain 
key contacts with the targeted protein surface. One emerging ap-
proach to elaborate such ligands consists in redesigning -helical 
peptides by combining -peptide and foldamer backbones in a sin-
gle chain. This has been successfully achieved with /-peptides by 
introducing regularly spaced -amino acid residues to replace 
-amino acids along the sequence of interest (16–18). Similarly, we 
have recently shown that peptide-oligourea replacements can be 
used to produce analogs of class B G protein–coupled receptor (GPCR) 
ligands with improved duration of action and to mimic protein ter-
tiary folds (19, 20). The choice of replacing a peptide segment with 
an oligourea insert is explained by the similarity and compatibility 
of the two helical folds and by the possibility to control the nature 
and the distribution of side chains at the surface of the oligourea 
helix (21). In the work on GPCR ligands (incretins), we actually 
scanned the entire helical portion of the peptide by swapping four 
consecutive amino acids for three ureido residues (AlauAlauAlau scan) 
to identify the most effective positions for oligourea inserts (19). 
However, the impact of replacing key anchor residues at sites that 
directly contact a protein surface by an oligourea foldamer has not 
yet been examined in detail. This is particularly relevant if one aims 
to develop short oligourea/peptide hybrids that can disrupt protein- 
protein interactions. To address this question and investigate how to 
appropriately position side chains along the oligourea backbone while 
retaining recognition properties, we selected antisilencing function 1 
(ASF1) histone chaperone as a protein target.
Histone chaperones regulate histone dynamics within chroma-
tin and the establishment of numerous epigenetic markers (Fig. 1A). 
Their dysfunction is associated with a number of pathologies in-
cluding aging-related diseases, pathogen infections, or cancer (22). 
ASF1 histone H3-H4 chaperone is critically involved in nucleosome 
assembly/disassembly and regulation of gene expression. In human, 
two ASF1 paralogs exist, called ASF1A and ASF1B. They share 70% 
of sequence identity and exhibit redundant and specific functions 
(23). Depletion of ASF1A/ASF1B or ASF1A + ASF1B has been shown 
to block proliferation in various cancer cell lines and to sensitize 
cells to chemotherapeutic agents such as doxorubicin (24). Overex-
pression of ASF1B in patients with breast cancer is a marker of poor 
prognosis (25), while ASF1A overexpression is observed in liver, 
prostate, or gastric carcinoma (26, 27). Together, these findings make 
ASF1A/ASF1B appealing biological targets for innovative antican-
cer treatments.
Details of the interaction between ASF1 and its protein partners 
including H3-H4 have been gathered at atomic resolution and in-
volve a binding surface fully identical for both paralogs (Fig. 1B) 
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(28, 29). The specific recognition of the heterodimeric H3-H4 com-
plex by ASF1 involves several shallow pockets distributed over a large 
surface area that renders the use of small-molecule–based approaches 
highly challenging.
By using an iterative structure-guided approach, we recently de-
signed a 26-residue peptide called ip4, ASTEEKWARLARRIAG-
AGGVTLDGFG exhibiting an affinity for ASF1 in the low nanomolar 
range. This peptide is composed of two parts, an -helical segment 
derived from histone H3 C terminal helix covalently linked to a  
strand originating from histone H4 C terminus. The high-resolution 
structure of ip4 in complex with ASF1 showed that its helical moiety 
interacts in a manner similar to histone H3 and harbors four of the 
five hot spot residues of the interaction (Lys2, Leu6, Arg9, and Ile10) 
(Fig. 1C and fig. S1) (30). Upon conjugation to a cell-penetrating 
peptide, ip4 was able to translocate into cells, impair cell prolifera-
tion, and perturb the cell cycle progression similarly to the silencing 
of ASF1 (30). Injection of this conjugate in mouse allografts reduced 
tumor growth. However, further exploration of its therapeutic poten-
tial was early compromised by its sensitivity to protease degradation.
To address this limitation, we developed a strategy based on ra-
tional design and foldamer chemistry to mimic the -helical part of 
ip4 and reproduce its binding mode. Here, we report the identifica-
tion of peptide-oligourea hybrids that recognize and bind to the sur-
face of ASF1 as well as the first x-ray structure at atomic resolution 
of a foldamer ligand bound to this histone chaperone.
RESULTS
Defining the minimal helical part required for ASF1 binding
At first, we synthesized the hexadecapeptide P1 corresponding to 
the -helical segment of ip4 as a reference of binding to ASF1. It 
contains the four anchor residues, Lys2, Leu6, Arg9, and Ile10, that 
are buried in specific pockets upon binding and mainly interact with 
Asp54, Asp88, Val94, Leu96, Tyr112, and Arg146 residues at the surface 
of ASF1 (Fig. 2 and fig. S1). P1 displays an affinity for the conserved 
domain of human ASF1A [hASF1A(1-156)] of 0.13 ± 0.04 M as 
measured by isothermal titration calorimetry (ITC) (Table 1 and 
fig. S2), which is a 10-fold decrease in affinity with respect to 
ip4. This peptide has an N-terminal capping motif (Ala-Ser-Thr-Glu) 
and a C-terminal Gly residue, also known to favor helix capping 
(31). Because our goal was to prepare minimal foldamer sequences, 
we next synthesized two derivatives of P1 missing the N-terminal 
capping motif and bearing either the C-terminal Gly residue (P2) or 
not (P3) (Fig. 2). These two peptides exhibited an affinity for hASF1A 
in the submicromolar range with Kd = 0.44 ± 0.02 M and 0.27 ± 
0.07 M for P2 and P3, respectively (Table 1 and fig. S2). P3 lacking 
both capping motifs showed a slight increase in affinity for ASF1 
compared to P2. We thus decided to focus our design on sequences 
lacking the terminal Gly residue. As in ip4, peptides P1 to P3 con-
tain a Trp in position 3 whose indole side chain enables favorable 
interactions with the apolar patch in ASF1 formed by Val92 and 
Tyr112. In our previous study, we showed that Trp3 combined with 
the N-terminal capping motif led to a 10-fold increase in the affini-
ty for ASF1 (30). With the aim to further improve apolar contacts 
with the surface of ASF1, we substituted Trp3 in P3 by a napthylal-























Fig. 1. The histone chaperone ASF1 target. (A) ASF1 belongs to the histone 
chaperone family whose members are involved in the transfer and assembly of 
parental histones (which are highly modified and carry essential epigenetic marks 
represented as stars) and newly synthetized histones during the process of DNA 
replication. (B) Structure of the ternary complex hASF1A(1-175)-H3-H4 (pdb 2io5). 




































Fig. 2. List of peptides (P) and 4-urea chimeras (C) synthetized and analyzed 
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same range as that of P3, but the analysis of the thermodynamic 
parameters indicated a more favorable contribution to binding en-
tropy (Table 1 and fig. S2).
Design of a peptide-oligourea chimera, mimicking 
the helical part of ip4
In a second round of design, we overlaid the x-ray crystal structure 
(pdb 6foh, Fig. 1C) of the Asf1-bound helical domain of ip4 (i.e., 
sequence P1) with representative oligourea x-ray crystal structures 
to identify the optimal location for oligourea segment insertion (21, 32). 
We decided to replace the six central -residues in the sequence of 
P3 and P4 by four consecutive urea-type residues (XaaU in Fig. 2). 
Models of the resulting 4-urea chimeras C1 and C2 were constructed 
assuming that the peptide-urea-peptide helices are fully formed. C1 
and C2 distinguish from one another solely by a TrpU or a NalU resi-
due at position 3, respectively. Both chimeras were properly docked 
to ASF1 surface without generating major clashes (fig. S1, middle). In 
this model, it was indeed possible to place three of the four anchor 
residues very close to their respective position in the ip4/ASF1 x-ray 
crystal structure ( carbons of LeuU5, Arg7, and Ile8, in C2 matching 
those of Leu6, Arg9, and Ile10 in P1 by less than 1.5 Å, respectively). 
However, the fourth anchor, Lys2, could not be properly aligned and 
lied away from the surface of ASF1, at more than 3 Å from its posi-
tion in the ip4/ASF1 x-ray crystal structure (fig. S1, middle).
The C1 and C2 chimeras were prepared by solid phase synthesis 
using microwave assistance and appropriately protected succinim-
idyl carbamate building blocks for the construction of the oligourea 
segment (see the Supplementary Materials for details, table S1, and 
fig. S3) (33). The binding affinities of C1 and C2 for ASF1 were first 
measured by ITC (Table 1 and fig. S2). C2 exhibits a low micromo-
lar affinity for the protein target (Kd= 2.7 ± 0.6 M), while C1 has a 
fourfold weaker affinity, showing the beneficial effect of NalU3 residue 
over TrpU3. Overall, C1 and C2 chimeras exhibit affinities 10 to 80 
times lower than the P1 to P4 peptide series, with a 13-fold affinity 
drop of C1 for ASF1 with respect to P4. In addition to binding af-
finities, microcalorimetry allowed us to measure the enthalpic and 
entropic contributions to the binding free energy for all peptides and 
chimeras (Table 1). Binding of P1 to P4 peptides to ASF1 is domi-
nated by both a significant enthalpic contribution (H ranging from 
−9.2 to −11.7 kcal/mol) and entropic cost (−TS ranging from 0.7 to 
2.9 kcal/mol). In contrast, the enthalpic contribution of ASF1 binding 
to chimeras C1 and C2 (and also of all other chimeras analyzed 
in this study C1 to C10) is much lower (H ranging from −3.6 to 
−1.7 kcal/mol) but is associated with a favorable entropic contribu-
tion (−TS varying from −4.8 to −2.7 kcal/mol). This entropy-driven 
binding mode of chimeras could likely reflect their favorable struc-
tural preorganization with modest conformational entropy cost upon 
binding and/or favorable contribution of hydrophobic effect to the 
binding free energy. The modest enthalpy gain of chimeras upon 
ASF1 binding may account for a less optimized interface in terms of 
packing, H-bond network and/or electrostatics.
NMR studies of chimera binding to ASF1
We next characterized the binding mode of C1 and C2 with ASF1 
by nuclear magnetic resonance (NMR) spectroscopy and used P1 
binding as a reference. Increasing amounts of C1 (or C2) were added 
to the N-terminal conserved domain of uniformly 15N-labeled 
hASF1A(1-156) (hereafter referred as 15N-hASF1A and see the Sup-
plementary Materials for 15N-labeled protein production). Results 
are depicted in Fig. 3 and fig. S4. The maximal chemical shift varia-
tions () were measured for most ASF1 residues at saturation con-
centration of chimeras or P1 (fig. S4) and mapped on ASF1 surface 
(Fig. 3C, right). The binding site on ASF1 of both C1 and C2 hybrid 
foldamers was found to match that of histone H3 helical domain, 
Table 1. Binding affinities and thermodynamic parameters of peptides/chimeras for hASF1A determined by ITC measurements and NMR 
spectroscopy. 
Peptide/chimera Kd (M) *,† (ITC) N*
H*
(kcal/mol) −TS* (kCal/mol) Kd (M)
‡ (NMR)
P1 0.13 ± 0.04 1.0 ± 0.1 −11.7 ± 0.4 2.9 ± 0.4 ND
P2 0.44 ± 0.02 1.1 ± 0.2 −10.3 ± 0.6 2.2 ± 0.6 ND
P3 0.27 ± 0.07 1.0 ± 0.1 −10.5 ± 0.8 2.2 ± 0.9 ND
P4 0.20 ± 0.09 1.0 ± 0.1 −9.2 ± 0.4 0.7 ± 0.6 ND
C1 10.6 ± 3.8 1.2 ± 0.2 −3.6 ± 0.5 −2.7 ± 0.7 18 ± 6
C2 2.7 ± 0.6 1.0 ± 0.1 −2.2 ± 0.1 −4.8 ± 0.2 4 ± 1
C3 4.6 ± 0.3 1.0 ± 0.1 −3.3 ± 0.1 −3.5 ± 0.7 6 ± 3
C4 13.3 ± 3.5 1.1 ± 0.2 −1.8 ± 0.4 −4.7 ± 0.5 15 ± 7
C5 6.6 ± 4.5 1.1 ± 0.1 −3.5 ± 1.4 −3.1 ± 0.2 ND
C6 4.3 ± 1.4 1.2 ± 0.1 −2.2 ± 0.3 −4.6 ± 0.4 8 ± 3
C7 15.4 ± 4.0 1.4 ± 0.2 −1.7 ± 0.2 −4.4 ± 0.4 16 ± 6
C8 ND ND ND ND 152 ± 90
C9 7.9 ± 0.3 1.2 ± 0.3 −3.5 ± 0.6 −3.0 ± 0.5 7 ± 4
C10 13.1 ± 4.1 1.2 ± 0.2 −1.9 ± 0.4 −4.3 ± 0.2 18 ± 4
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also highlighted upon addition of P1 (Fig. 3C, left, and fig. S4). 
Nonetheless, addition of P1 also led to chemical shift perturbations 
for some ASF1 residues from Val60 to Phe72, matching the B-domain 
binding site (34). This corresponds to a nonspecific binding site for P1. 
C1 and C2 only interacted with the histone H3 binding site and did not 
give rise to such nonspecific binding (Fig. 3C, right, and fig. S4).
Upon 15N-ASF1 titration with C2 as ligand (and also with all 
other chimeras C1 to C10 analyzed in this study), we observed a fast 
exchange rate, as illustrated by the recorded chemical shift variation 
() of some hASF1A residues [ of Thr93 and Ile97 displayed in 
Fig. 3B (middle)]. In contrast, P1 to P4 peptides showed a slow ex-
change regime upon interaction with ASF1 surface (Fig. 3B, top for 
P1 titration). Although it is not possible to quantify the kinetic pa-
rameters from these NMR experiments, the fast exchange regime 
could reflect faster association/dissociation rates of the ASF1-chimera 
complexes compared to the ASF1-peptide ones. This hypothesis is 
compatible with a less optimized interface of the chimeras with 
respect to the peptides and consistent with the ITC results dis-
cussed above.
The fast exchange regime observed during the NMR titration 
experiments with the chimeras C1 and C2 allowed us to plot titration 
curves for several ASF1 residues interacting with each chimera [see 
the Materials and Methods section, Fig. 3B (right), and fig. S5]. The 
fitted affinity values are in good agreement with those measured 
by ITC (Table 1, last column).
As additional proof of the relevancy of our foldamer design, we 
synthesized the -peptide P5 having the exact side-chain composi-
tion of C2 (Fig. 2). No binding to ASF1 was detected with this pep-
tide by ITC (fig. S2). The chemical shift mapping presented in fig. 
S4 shows that upon titration of ASF1 with P5 as ligand, we only 
observed small shifts of ASF1 residues in the B-domain nonspecific 
binding region. These results confirm that the binding of C2 in the 
H3 binding pocket of ASF1 corresponds to specific interactions.
High-resolution structure of C2 bound to ASF1
With the aim of gaining additional structural information about the 
binding mode of the peptide-oligourea hybrids to ASF1, we solved 
the cocrystal structure of C2 bound to hASF1A conserved domain 
at 1.8-Å resolution. The structure confirms that overall C2 binds 
ASF1 with the expected geometry [Fig. 4, figs. S1 (right) and S6A, 
and table S2]. The four anchoring side chains are positioned in a 


























ASF1 + P1 ASF1 + C2C
Histone H3 
binding site
B domain binding 
site (nonspecific)
∆δ
Fig. 3. NMR analysis of P1 and C2 binding to ASF1. (A) Overlay of the SOFAST HMQC spectra of 15N-hASF1A alone and after addition of a twofold excess of P1 or C2 (in 
gray, green, and magenta, respectively). The region indicated with a black box is magnified in (B, left and middle). (B) Top and middle: Overlay of five spectra measured 
at different concentrations of P1 and C2, respectively, with a rainbow color code from blue to red (in dark blue, free hASF1A, and in red, after addition of twofold ex-
cess of peptide/chimera), for the region boxed in (A) showing the modification signals of Thr93 and Ile97 upon titration. The position of the signal in the bound state is 
indicated by an arrow. Bottom: Representative titration curve for ASF1 residues Thr93 and Ile97 using the same color code. The fitted curve is depicted as a dashed line. 
(C) Chemical shift mapping on hASF1A surface after addition of a twofold excess of P1 or C2 as indicated. Increasing color scale corresponds to higher chemical shift 
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This finding was unexpected, since in the original design with a 
canonical straight hybrid helix, Lys2 side chain was not oriented 
toward its anchoring position (Fig. 4E, middle). As regard the pep-
tide/urea chimera backbone, it adopts a helical conformation. Yet, 
the urea helix is unexpectedly distorted with respect to a regular 
2.5 helix uniquely composed of urea-type units (Fig. 4, C and E, right) 
(35). The backbone hydrogen bond network is disrupted between 
NalU3 carbonyl and the amides of the urea bond LeuU5-GlnU6, and 
a water molecule bridges LeuU5 carbonyl and Ile8 amide bond 
(Fig. 4C). It is unlikely that this distortion is an intrinsic conse-
quence of the hybrid character of the oligomer sequence as previous 
structural investigations of model peptide-oligourea hybrids showed 
formation of homogeneous helices without disruption of the H-bond 
network between the two segments (21). Alternatively, a mutual con-
formational adaptation between the protein and C2, together with 
the establishment of new specific contacts between the foldamer 
backbone and the protein, may account for this distortion. Several 
observations support this interpretation. First, a direct H-bond be-
tween the phenol group of Tyr112 and the main chain urea carbonyl 
of residue LeuU5 is formed (Fig. 4, C and D), and the intramolecular 
H-bond network of the chimeric helix is locally interrupted at this 
residue. This distortion can be further stabilized by the insertion of 
the LeuU5-Ile8 water bridge (Fig. 4, C and D). Overall, the orientation 
of several ASF1 side chains (such as Tyr112 and Arg145) is modified 
upon C2 binding when compared to the ip4 binding (Fig. 4D). This 
side-chain conformational rearrangement is possibly taking place 
for shaping the surface to the slight modifications in LeuU5 and Ile8 
geometry. Last, the helix distortion induces a bending favorable for 
the anchor residue Lys2 to interact with the acid loop of ASF1. 
Moreover, the tilted conformation of the hybrid helix facilitates the 
interaction of Lys2 with Asp88 as for ip4 bound to ASF1 (Fig. 4E and 
fig. S6B). Together, these observations highlight the remarkable 
plasticity of the urea chimeric helix, able to kink to adapt ASF1 
surface and optimize interactions with the four anchoring residues.
A second noticeable feature of bound C2 in the crystal structure 
is that the NalU3 residue does not interact with the expected ASF1 
residues (Tyr112 and Val92). In contrast, the NalU3 side chain associ-
ates with a symmetrical ASF1 molecule in a pocket containing the 
Val60-Phe72 stretch corresponding to the B-domain binding region 
of ASF1 (fig. S6C). This interaction is most probably a crystalliza-
tion artifact since this binding site was not highlighted in the NMR 
chemical shift mapping in solution upon addition of C2 to 15N- 
hASF1 as mentioned in the previous section (Fig. 3C and fig. S4). 
To further validate this hypothesis, we synthetized two additional 
variants of C2 equipped either with a smaller (hPheU3 in C3) or 
no aromatic ring (AlaU3  in C4) (Fig. 2). We next measured their 
Fig. 4. Crystal structure of chimera C2 in complex with ASF1 compared to the binding mode of P1. (A) Front view of ASF1 (gray surface) bound to the peptide P1 
(green cartoon representation). Selected side chains of P1 residues contacting ASF1 surface are highlighted. (B) Crystal structure of C2 (sticks representation) bound to 
ASF1 (gray surface). C2 -amino acids are colored in green, and the four ureido-residue groups are in pink. (C) Detailed view of the conformation of C2 in its central region 
with the same color code as in (B). Hydrogen bonds are shown with orange dashed lines; selected water molecules are shown with red spheres. (D) Overlay of P1 and C2 
bound to ASF1. C2 and P1 backbones are shown with sticks or cartoon, respectively. For the sake of clarity, only the side chain of the two ASF1 residues with the greatest 
structural variations between the two structures is shown (in light gray for C2-bound ASF1 and in black for P1-bound ASF1). Most side chains of the chimera/peptide are 
also omitted; only LeuU5/Leu6 and Leu8/Leu10 of C2 and P1, respectively, are shown in sticks and labeled. (E) ASF1 bound to P1, modeled C2, and C2 in the crystal structure 
are depicted on the left, middle, and right, respectively. ASF1 is displayed as a gray surface; peptides and chimera backbones are displayed as sticks with hydrogen bonds 
as orange dashed lines. The four anchor residue side chains are shown as spheres and labeled. The water molecule bridging LeuU5 carbonyl and Ile8 amide bond is also 
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respective affinity for ASF1 by ITC and NMR (Table 1 and fig. S2). 
A slight decrease in affinity (twofold) was observed for C3, whereas 
a more pronounced effect on binding was measured with C4. These 
data support the conclusion that the naphtyl ring of NalU3 partici-
pates in the interaction, despite the absence of direct contact in the 
x-ray crystal structure of the ASF1/C2 complex. We thus conclude 
that the chimera C2 at the NalU3 residue could adopt a different 
rotamer in solution than the one selected in the crystal, but this con-
formation might be rather dynamic due to sparse packing. Together, 
structural data reported here validate the mode of interaction of C2 
with ASF1 as well as our general design approach.
We next attempted to modulate the recognition of ASF1 by hybrid 
foldamers through sequence manipulations. As already discussed in 
the x-ray crystal structure of ASF1/C2 complex, Lys2 is properly ori-
ented and establishes electrostatic interactions with ASF1-Asp88 (fig. 
S6B). We evaluated whether additional contacts could be established 
by replacing Lys2 by an Arg residue (C5, Fig. 2). However, the binding 
affinity of C5 measured by ITC was not improved (Table 1). We also 
explored the possibility to increase the binding affinity by varying 
LeuU5 side chain. Four additional chimeras were synthetized with 
several alkyl and aryl side chains at position 5, NleU, hPheU, NalU, and 
diFU in the chimera C6 to C9, respectively (Fig. 2). Although some 
were equally tolerated (NleU in C6 and diFU in C9), none of these 
modifications improved the binding affinity of C2 (Table 1 and figs. 
S2 and S5). We lastly evaluated the consequence of extending the 
N terminus of C2 with a capping box and synthesized C10 terminated 
by the Ala-Ser-Thr-Glu tetrad (Fig. 2, Table 1, and figs. S2 and S5). In 
contrast to P1, this modification did not lead to a tighter binding. This 
result can, in part, be explained by the fact that the helix in ASF1-
bound C2 is tilted compared to the cognate  helix in ip4, so the ex-
tension of the helix may potentially induce a clash with ASF1-Ala48 
and Glu49 residues.
The chimera C2 is protected from proteolysis 
and penetrates in cells
We have previously shown that the oligourea backbone is far less 
susceptible to proteolysis than -peptides and can be used as molec-
ular insert to increase the stability of bioactive peptides (11, 19). To 
evaluate whether  to urea replacement in the sequence of ASF1 li-
gands provide compounds with improved resistance to proteolytic 
degradation, we quantified the degradation rate of C2 in human 
plasma and compared it to that of P4 (Fig 5). The halftime of P4 in 
human plasma was determined by following the decay of the intact 
molecule by liquid chromatography–mass spectrometry (LC-MS). 
In these conditions, P4 had a lifetime of about 1 hour. In contrast, 
C2 was largely resistant to protease degradation even after 8 hours 
in human plasma and that despite the presence of flanking -amino 
acid residues at both termini of its sequence. We thus conclude that 
replacing about half of -amino acid residues by ureido residues in 
P4 is enough to protect the peptide hybrid against serum proteases. 
The ability of this compound to penetrate into cells was visualized 
by confocal microscopy using a fluorescein isothiocyanate (FITC)–
tagged version of C2 and compared to FITC-P4 (fig. S7A). We ob-
serve green fluorescent dots inside cells for both compounds, showing 
effective cell penetration and their probable association with intra-
cellular vesicles. Quantification of chimera/peptide accumulation 
in cells was measured using flow cytometry. FITC-C2 penetrates 
cells significantly, even at low extracellular concentrations (below 
the micromolar), but its accumulation remains a factor of ~5 lower 
compared to FITC-P4 (fig. S7, B and C).
DISCUSSION
We have designed the first generation of ASF1 ligands with a central 
foldamer backbone by engineering peptide sequences derived from 
the C terminus of histone H3 and introducing oligourea inserts. We 
demonstrate that these sequence specific peptide-foldamer hybrids 
bind their biological target with Kd in the low micromolar range. 
We also report a unique x-ray crystal structure of a complex be-
tween ASF1 and the most potent compound in the series. In good 
agreement with biomolecular NMR studies, this structure shows 
that the helical bound conformation and the binding mode of the 
cognate peptide domain is retained. Notably, the crystal structure 
also shows mutual plasticity of the two partners upon binding and 
the formation of a noncanonical bent helical structure resulting from 
a modification of the typical intramolecular three-center H-bond 
pattern of oligoureas by a protein side chain (Tyr112). This alter-
ation allows helix bending favorable for the four anchor residues to 
interact simultaneously. Here, the plasticity of the helical oligourea 
backbone can thus be seen as an advantage asset and allow the fol-
damer to shape itself to the protein surface. In another noteworthy 
example reported recently, flexible units were deliberately intro-
duced in aromatic oligoamide foldamers to engineer helix destabi-
lization and sense chirality at the protein surface (36). Despite this 
mutual adaptation of the chimera and the protein, the low enthal-
pic contribution to the binding free energy measured by microcal-
orimetry gives room for further optimization of the packing at the 
complex interface. We also demonstrate that inserting four ureido 
residues in the center of the helix was sufficient to considerably 
protect against proteolysis in particularly stringent conditions. This 
increased stability of foldamers in biological fluids bodes well for 
the development of ASF1 ligands with prolonged duration of ac-
tion in vivo. Another interesting feature of chimera C2 is its ability 
to penetrate into cells, although to a lesser extent compared to the 
peptide P4. This difference could be due to the different net charge 
of these compounds (+2 and +3 for C2 and P4, respectively). The 
bioavailability of these compounds and their affinity for the target 
still need further optimization for effective inhibition of ASF1  in 
cells. The strategy reported previously for peptide ip4 consisting in 
connecting a central binding element to a distant anchor point via 
a tailored spacer has recently been applied to foldamer-peptide hy-
brids (37) and is likely to apply to chimera C2 to eventually con-











Fig. 5. Stability against protease degradation in human plasma. Stability 
against protease degradation in human plasma. The percentage of peptide P4 or 
chimera C2 detected by LC-MS is reported as a function of time. Error bars repre-
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Foldamer/peptide hybrids were synthesized on solid support using 
succinimidyl (2-azidoethyl)carbamate as activated monomers for the 
elongation of oligourea segments, as previously reported (figs. S8 to S11) 
(19, 32, 33). Full details on chemical synthesis and purification of peptides 
and foldamers C1 to C10 are given in the Supplementary Materials.
Expression and purification of ASF1
Recombinant human ASF1 [hASF1A(1-156)] was purified as already 
described from expression in Escherichia coli of a (His)6–glutathione 
S-transferase (GST)–TEV site–Asf1 fusion protein using the pETM30 
plasmid (38). Briefly, soluble (His)6-tagged GST fusion protein was 
purified on reduced glutathione agarose beads (Sigma- Aldrich). After 
cleavage with recombinant (His)6-Tobacco Etch Virus Protease (TEV) 
protease at room temperature overnight, the (His)6-GST tag and the 
protease were trapped in a nickel-charged nitrilotriacetic acid (NTA) 
chelate immobilized onto agarose column (Macherey Nagel). The 
flow-through fraction containing ASF1 protein was further purified 
by anion exchange chromatography using a Resource Q 6-ml column 
(GE Healthcare). ASF1 was then concentrated using an Amicon 
device (Millipore), and the buffer was replaced with a 50 mM tris-HCl 
(pH 7.5). Unlabled ASF1 used for ITC experiments was purified from 
pellets of bacteria grown in LB medium and uniformly labeled ASF1 
from bacteria gown in M9 minimal media supplemented with 
(15NH4)Cl (0.5 g/liter; Eurisotop) as the sole nitrogen source and 
or 13C glucose (2 g/liter; Eurisotop).
Isothermal titration calorimetry
All ITC experiments were performed in a VP-ITC titration calorim-
eter (Microcal/Malvern) at 20°C, in a 50 mM tris-HCl (pH 7.5) buf-
fer. Protein and peptides concentrations were set to values of 10 and 
200 M, respectively. Protein and peptide samples were prepared in 
the same buffer and degassed (ThermoVac, Malvern). After equili-
brating the cell at 298 K, the rotating syringe (310 rpm) injected at 
intervals of 280 s, 6 l of aliquots of peptide solution into the ASF1 
solution previously introduced in the sample cell, until saturation 
was observed. Raw ITC data were processed with the Origin 7.0 
Software (OriginLab, Malvern) using the One-Set of Sites fitting 
model. All ITC experiments were performed at least in duplicate. One 
representative curve for each peptide/chimera is shown in fig. S2.
NMR studies–1H-15N heteronuclear  
single-quantum coherence
The binding mode of the constrained peptides was assessed using 
NMR spectroscopy. NMR experiments were performed at 293 K or 
298 K on Bruker Avance II 600 MHz spectrometer equipped with a 
proton-optimized triple resonance NMR ‘inverse’ cryoprobe (TCI), 
(Bruker). Purified uniformly labeled 15N hASF1A(1-156) was con-
centrated to 40 M and exchanged in NMR buffer [50 mM tris-HCl 
(pH 7.5), 0.1 mM EDTA, 0.1 mM dextran sulfate sodium (DSS), 
0.1 mM NaN3, protease inhibitor cocktail (at the concentration rec-
ommended by the provider, Roche), and 10% D2O]. Proton chemical 
shifts (in parts per million) were referenced relative to internal 
DSS, and 15N reference was set indirectly relative to DSS using 
frequency ratios (39). NMR data were processed using Topspin (Bruker) 
and analyzed using Sparky (T. D. Goddard and D. G. Kneller, Univer-
sity of California San Francisco). Amide assignment was taken 
from (38). The titration experiments were performed by adding 
increasing amounts of concentrated peptide or chimera to the ASF1 
sample. At each ASF1:peptide ratio, a two dimensional 1H-15N 
SOFAST HMQC (heteronuclear multiple-quantum coherence) spec-
trum was recorded. Changes in chemical shift were measured for all 
resonances for all recorded spectra. Assignments were obtained by 
following progressive variations of chemical shifts upon titration or 
with a standard triple resonance method using a uniformly 15N-13C–
labeled ASF1 sample complexed with an excess of peptide or 
chimera. Chemical shift variation was calculated with the following 
formula  √ 
_________________________
   (  HN 
b  −   HN 
f  ) 
2
 +  (0.17( N 
b  −   N 
f  ) ) 
2
, where  represents mea-
sured chemical shift value. b or f refers to the bound or free form, 
respectively, HN or N to the amide proton or nitrogen, respectively. 
The factor 0.17 corresponds to the scaling factors used to normalize the 
magnitude of the proton and nitrogen chemical shift changes (in parts 
per million) (40). At saturation of the peptide or chimera, the maximal 
chemical shift variation was plotted as a function of the residue number 
for 138 residues of the 156 residues of hASF1A(1-156) (fig. S3). This 
corresponds to 96% of the expected values, considering the 12 prolines.
The exchange rate between bound and free forms was rapid 
upon addition of the chimeras C1 to C11 (Fig. 3A, lower middle for 
C2). The dissociation constant of the complex was fitted from the 
plot of the normalized chemical shift variation in function of total 
chimera concentration (as shown for two residues in Fig. 3A, bottom 
right) using the following equation:   N =  [ ( c A +  c C +  K d ) − 
√ 
____________________
   ( c A +  c C +  K d ) 2 − 4  c A  c C  ] / 2 , where cA represents the total concen-
tration of ASF1, cC represents the total concentration of added chimera, 
and Kd represents the dissociation constant. N is the chemical shift 
variation normalized with the maximal chemical shift variation mea-
sured at saturating concentration of chimera. For each chimera, the fit 
was performed independently ASF1 residues belonging to the three 
main regions showing significant chemical shift changes: Ala48, 
Glu49, Glu51, Val90, Thr93, Ile97, Arg108, Val109, and Tyr111. These res-
idues were chosen because (i) they show significant chemical shift 
variation (more than 0.07 ppm) and (ii) the signals allowed a precise 
measure of the chemical shift at all chimera concentrations (no sup-
positions and no slow-intermediate exchange rate). The value of the 
dissociation constant reported in Table 1 corresponds to the mean 
Kd value and standard deviation (SD) fitted for these residues. Curves 
and fits are shown in fig. S4.
Crystallization, data collection, and structure determination
hASF1A(1-156) and C2 were mixed, and the complex was concen-
trated to 8.6 mg/ml in a buffer 50 mM tris-HCl (pH 7.4). Crystals of 
the complex were grown by sitting drop vapor diffusion at 20°C 
against reservoir solution containing 100 mM sodium citrate (pH 4.2), 
300 mM LiSO4, and 26% PEG3350 [Poly(ethylene glycol) Average 
Molecular Mass 3350]. Crystals were soaked in a 100 mM sodium ci-
trate (pH 4.2), 300 mM LiSO4, 26% PEG3350, and 20% glycerol 
cryo-protectant solution before being flash-frozen in liquid nitro-
gen. Diffraction data were collected on the PROXIMA-1 beamline at 
the Synchrotron SOLEIL (Saint Aubin, France) at a temperature of 
100°K with an x-ray wavelength of 0.97857 Å. Diffraction images 
recorded with PILATUS 6M detector were processed using the XDS 
package (41). Best datasets were obtained from two crystals of 
hASF1A(1-156)–C2 belonging to space group P1, which diffracted 
up to 1.8-Å resolution. The two datasets were merged and scaled, 
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molecular replacement using MOLREP (42) with the human ASF1A 
structure [chain A of Protein Data Bank (PDB) entry 2i32] as the 
model probe. Best solution contained two complexes per asymmetric 
unit. Model building was performed with the Coot software (43), 
and structure refinement was achieved with BUSTER version 2.10 
(44, 45). Final refinement statistics are presented in table S2. Struc-
ture representations presented in all figures were drawn with PyMOL 
software (Schrödinger).
Proteolysis assay
Stock solutions of the peptide P4 and the chimera C2 were prepared 
at a concentration of 250 M in water. Stock solution of human 
plasma was prepared in water as aliquots. Each aliquot was diluted 
1/4 with a solution of 0.1 M phosphate-buffered saline (PBS) (pH7.4) 
buffer before use. Stability of these molecules in human plasma was 
assessed by conducting protease reaction at 37°C. A total of 392 l 
of the solution of human plasma in PBS was first incubated for 
15 min at 37°C. To this, preactivated enzymatic solution was added 
8 l of the solution of the tested compound (final concentration, 
5 M). At the indicated times (0, 10, 20, 40, 60, 120, 240, and 480 min), 
an aliquot of 45 l was collected and added to 150 l of acetonitrile 
(ACN) to quench the reaction. The samples were frozen at −80°C 
before analysis. The frozen samples were defrosted, stirred with a 
vortex (2 min), and lastly centrifuged (16°C, 5 min, 18,000g). A portion 
of the resulting supernatant was submitted to concentration under 
high vacuum to remove ACN excess and then resuspended in a solu-
tion of water +0.1% formic acid/ACN + 0.1% formic acid (95:5, v/v). 
Reaction progress over time was quantified by UPLC-MS analysis. 
The time course of inhibitor degradation was determined by inte-
grating the area of the peak from the extracted ion chromatogram. 
All experiments were carried out in triplicates for both compounds. 
The chromatography conditions were as following: Column: 
Phenomenex Aeris PEPTIDE 1.7 m XB-C18: 150 mm × 2.1 mm; 
mobile phase: A = water with 0.1% formic acid, B = acetonitrile with 
0.1% formic acid; gradient: A/B (95:5) for 1.0 min to A/B (60:40) over 
5 min to A/B (90:10) for 1.5 min to A/B (95:5) for 2.5 min; flow rate: 
0.5 ml/min; temperature: 60°C; instrument: Dionex Ultimate 3000 
(Thermo Fisher Scientific); detection: electrospray ionization–FTMS 
(Fourier Transform Mass Spectrometry) in positive mode (150 to 
2000 mass/charge ratio) on a Q Exactive instrument (Thermo 
Fisher Scientific).
Cell penetration assays
Human cancer cell lines U2OS [osteosarcoma (ATCC HTB-96)] were 
cultured in Dulbecco’s modified Eagle medium (Sigma-Aldrich) 
containing 10% (v/v) fetal bovine serum (FBS; Sigma-Aldrich) and 
penicillin (100 U/ml) and streptomycin (100 g/ml) (Gibco) at 
37°C in a humidified incubator with 5% CO2. For quantification of 
peptide/chimera penetration by fluorescence-activated cell sorting, 
U2OS cells were seeded in 24-well plates at 50,000 cells per well and 
incubated for 48 hours at 37°C and 5% CO2. Then, FITC peptide/
chimera was added directly into the culture medium (v/v) at final 
concentrations of 0.5, 1, 3, 5, or 10 M, and cells were incubated 
24 hours at 37°C and 5% CO2. The culture medium was removed, 
and cells were rinsed twice with PBS (Sigma-Aldrich, D8537). Cells 
were then incubated with trypsin (5 mg/ml)–EDTA (2 mg/ml) 
(Sigma-Aldrich, T4174) at 37°C and 5% CO2, with dual purpose of 
detaching the cells and removing most of the peptides/chimera 
nonspecifically adhering to the extracellular membrane (46). Cells 
were transferred to 1.5-ml tubes and washed twice with PBS buffer 
complemented with 2% FBS and 2 mM EDTA. Propidium ionide 
(PI) was added at 1 g/ml final concentration to probe dead/dying 
cells. Flow cytometry analysis was then immediately performed using 
a Guava easyCyte HT instrument (Millipore) with a total of 10,000 
events recorded per sample. The FITC fluorescence intensity of 
peptide/chimera was measured for intact cells in the green channel 
(Ex 488 nm and Em 525/30 nm). The percentage of damaged cells 
was measured in the red channel with PI fluorescence (Ex 488 nm 
and Em 680/30 nm). It was less than 10% for all samples.
For visualization of peptide/chimera penetration by microscopy, 
U2OS cells were seeded into the wells of a collagen-coated (Sigma- 
Aldrich) optical 96-well culture plate (Ibidi) at a final density of 
1500 cells per well. Plates were then incubated for 48 hours at 37°C 
and 5% CO2 to allow cell adhesion. The supernatant was removed 
and replaced with fresh medium containing either FITC-P2, FITC-P4, 
or H2O (vehicle) as control, and plates were incubated for 24 additional 
hours at 37°C and 5% CO2. Cells were then fixed with paraformal-
dehyde [4% (w/v) final], and nuclear DNA was fluorescently labeled 
by Hoechst 33342 (2 g/ml final). After an overnight incubation at 
4°C, supernatants were removed by aspiration and replaced by 
100 l of PBS. Plates were imaged on a confocal microscope (Nikon 
Ti2 equipped with a spinning disk module) in the blue (Hoechst) 
channel (Ex 405 nm and Em 460/50 nm) and in the green (FITC) 
channel (Ex 488 nm and Em 535/50 nm) at ×20 magnification. 
Images were imported in Fiji (47), and image and contrast were 
adjusted using the image (FITC-C2 at 10 M) as reference for com-
parison purposes.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/12/eabd9153/DC1
View/request a protocol for this paper from Bio-protocol.
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